The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a https://jonasshrh005139.wikipresses.com/6654568/retatrutide_vs_tirzepatide_a_comparative_analysis